These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3131043)

  • 1. Valproic acid and the liver.
    Cotariu D; Zaidman JL
    Clin Chem; 1988 May; 34(5):890-7. PubMed ID: 3131043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carnitine in the treatment of valproic acid-induced toxicity.
    Lheureux PE; Hantson P
    Clin Toxicol (Phila); 2009 Feb; 47(2):101-11. PubMed ID: 19280426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatotoxicity in rat following administration of valproic acid.
    Sugimoto T; Woo M; Nishida N; Takeuchi T; Sakane Y; Kobayashi Y
    Epilepsia; 1987; 28(2):142-6. PubMed ID: 3102219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update.
    Guo HL; Jing X; Sun JY; Hu YH; Xu ZJ; Ni MM; Chen F; Lu XP; Qiu JC; Wang T
    Curr Pharm Des; 2019; 25(3):343-351. PubMed ID: 30931853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity.
    Siemes H; Nau H; Schultze K; Wittfoht W; Drews E; Penzien J; Seidel U
    Epilepsia; 1993; 34(2):332-46. PubMed ID: 8453944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired fatty acid oxidation in children on valproic acid and the effect of L-carnitine.
    Kossak BD; Schmidt-Sommerfeld E; Schoeller DA; Rinaldo P; Penn D; Tonsgard JH
    Neurology; 1993 Nov; 43(11):2362-8. PubMed ID: 8232957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. III. Influence of fasting.
    Löscher W; Wahnschaffe U; Hönack D; Drews E; Nau H
    Epilepsy Res; 1993 Dec; 16(3):183-94. PubMed ID: 8119269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Valproate-associated hepatotoxicity--pathogenesis, clinical aspects, therapy and prevention].
    Siemes H; Nau H
    Klin Padiatr; 1991; 203(6):411-9. PubMed ID: 1758143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproate hepatotoxicity syndrome: hypotheses of pathogenesis.
    Stephens JR; Levy RH
    Pharm Weekbl Sci; 1992 Jun; 14(3A):118-21. PubMed ID: 1502010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review.
    Silva MF; Aires CC; Luis PB; Ruiter JP; IJlst L; Duran M; Wanders RJ; Tavares de Almeida I
    J Inherit Metab Dis; 2008 Apr; 31(2):205-16. PubMed ID: 18392741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
    Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal metabolism of valproic acid in fatal hepatic failure.
    Kochen W; Schneider A; Ritz A
    Eur J Pediatr; 1983 Oct; 141(1):30-5. PubMed ID: 6416845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects.
    Appleton RE; Farrell K; Applegarth DA; Dimmick JE; Wong LT; Davidson AG
    Can J Neurol Sci; 1990 May; 17(2):145-8. PubMed ID: 2113424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between glucuronide conjugate levels and hepatotoxicity after oral administration of valproic acid.
    Lee MS; Lee YJ; Kim BJ; Shin KJ; Chung BC; Baek DJ; Jung BH
    Arch Pharm Res; 2009 Jul; 32(7):1029-35. PubMed ID: 19641884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity.
    Fisher E; Siemes H; Pund R; Wittfoht W; Nau H
    Epilepsia; 1992; 33(1):165-71. PubMed ID: 1733752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
    Goto S; Seo T; Hagiwara T; Ueda K; Yamauchi T; Nagata S; Ando Y; Ishitsu T; Nakagawa K
    J Pharm Pharmacol; 2008 Feb; 60(2):267-72. PubMed ID: 18237476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of L-carnitine supplementation on acute valproate intoxication.
    Murakami K; Sugimoto T; Woo M; Nishida N; Muro H
    Epilepsia; 1996 Jul; 37(7):687-9. PubMed ID: 8681902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal metabolism of carnitine and valproate in a case of acute encephalopathy during chronic valproate therapy.
    Murakami K; Sugimoto T; Nishida N; Kobayashi Y; Kuhara T; Matsumoto I
    Brain Dev; 1992 May; 14(3):178-81. PubMed ID: 1514659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation.
    Schiavo A; Maldonado C; Vázquez M; Fagiolino P; Trocóniz IF; Ibarra M
    Eur J Pharm Sci; 2023 Apr; 183():106399. PubMed ID: 36740101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproic acid induced liver injury: An insight into molecular toxicological mechanism.
    Ezhilarasan D; Mani U
    Environ Toxicol Pharmacol; 2022 Oct; 95():103967. PubMed ID: 36058508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.